MRNS - マリナス・ファ―マシュ―ティカルズ (Marinus Pharmaceuticals Inc.)

MRNSのニュース

   The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO  2020/09/17 11:59:47 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Myokardia Inc (NASDAQ: MYOK ) Nevro Corp (NYSE: NVRO ) Novocure Ltd (NASDAQ: NVCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Revance Therapeutics Inc (NASDAQ: RVNC ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 16) PainReform Ltd (NASDAQ: PRFX ) Pandion Therapeutics Inc (NASDAQ: PAND ) SILENCE THERAPE/S ADR (NASDAQ: SLN ) Stocks In Focus Moderna Announces 2 R&D Collaborations For Up To $880M Moderna Inc (NASDAQ: MRNA ) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) announced a three-year strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for cystic fibrosis.
   The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO  2020/09/16 12:00:28 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than doubled on its Wall Street debut) Repare Therapeutics Inc (NASDAQ: RPTX ) Revance Therapeutics Inc (NASDAQ: RVNC ) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) Histogen Inc (NASDAQ: HSTO ) PainReform Ltd (NASDAQ: PRFX ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) SILENCE THERAPE/S ADR (NASDAQ: SLN ) Stocks In Focus Roche Gets Label Expansion For Cancer Screening Test Roche Holdings AG Basel (OTC: RHHBY ) announced FDA approval for the expanded use of CINtec PLUS Cytology, its first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus.
   Why This Epilepsy Study Is Huge for Marinus Pharmaceuticals  2020/09/15 16:35:46 24/7 Wall street
   NEE, NVAX among premarket gainers  2020/09/15 12:36:16 Seeking Alpha
Marinus Pharmaceuticals (MRNS +61% after ganaxolone successful in pivot study in rare type of epilepsy. Plus Therapeutics (PSTV +43% on fast track status f
   MRNS, KLDO, NKLA and SMG among after-hours movers  2020/09/14 21:38:40 Seeking Alpha
Gainers: MRNS +63.5%. EXLS +6.7%. NEE +6.4%. CWH +5.4%. SMG +5.1%. Losers: KLDO -9.0%. NKLA -8.0%. INTC -6.5%. ALLT -6.2%. CAL -5.7%.
   Marinus Pharmaceuticals: 2Q Earnings Snapshot  2020/08/06 15:18:34 SFGate
RADNOR, Pa. (AP) _ Marinus Pharmaceuticals Inc. (MRNS) on Thursday reported a loss of…
   Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results  2020/08/06 11:30:00 Business Wire
RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #BizUpdate--Marinus Pharmaceuticals provides an update on its clinical development activities and reports financial results for the second quarter of 2020.
   Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder (CDD)  2020/07/30 11:30:00 Business Wire
RADNOR, Pa.--(BUSINESS WIRE)-- #CDKL5--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s product candidate ganaxolone for the treatment of CDKL5 deficiency disorder (CDD), a rare refractory form of pediatric epilepsy. “We are pleased that ganaxolone has received
   Marinus Pharma inks $60M stock sales deal with JMP (NASDAQ:MRNS)  2020/07/10 10:26:56 Seeking Alpha
Marinus Pharmaceuticals (NASDAQ:MRNS) has filed a prospectus for a $250M mixed shelf offering. It has also entered into an agreement with JMP Securities fo
   Marinus Pharmaceuticals Provides Pipeline Update  2020/06/30 11:00:00 GlobeNewswire
Status Epilepticus pivotal Phase 3 trial on-track to begin in Q3 2020CDKL5 Deficiency Disorder Phase 3 trial results in Q3 2020 First patient enrolled in…
   MRNA Stock Down 10%, Moderna Didn’t Produce Data to Assessing COVID-19 Vaccine  2020/05/20 11:32:41 Coinspeaker
Moderna announced COVID-19 vaccine trial results, but experts said this information is not enough to assess mRNA-1273. MRNS stock is down.
   The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace  2020/05/03 12:45:37 Benzinga
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ). Merck disappointed by lowering its outlook, although sell-side stayed positive on the prospects. Presentations at the American Association of Cancer Research Virtual Conference created some volatility. Verastem Inc (NASDAQ: VSTM ) became a casualty of "not-so-impressive" clinical data on its Phase 1 asset VS-6766 that targets KRAS mutant advanced solid tumors. The stock shed about 57% to a low of $1.77 before recovering some lost ground. Here are the key catalysts for the unfolding week. Conferences SunTrust Robinson Humphrey 6th Annual Life Sciences Summit (Virtual Conference): May 5–6 Maxim Group M-Vest Infectious Disease Virtual Conference: May 5 Related Link: A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio Clinical Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) is scheduled to present new data from the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene therapy in wet age-related macular degeneration.
   Marinus updates on ganaxolone in epilepsy  2019/12/09 12:26:46 Seeking Alpha
Marinus Pharmaceuticals (MRNS) announces clinical and regulatory updates for its orphan seizure programs in tuberous sclerosis complex ((TSC)), CDKL5 defic
   Zacks Investment Research Lowers Marinus Pharmaceuticals (NASDAQ:MRNS) to Hold  2019/11/16 22:42:12 Modern Readers
Zacks Investment Research cut shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a buy rating to a hold rating in a research note issued to investors on Tuesday morning, Zacks.com reports. According to Zacks, “Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and […]
   Marinus Pharmaceuticals Inc (NASDAQ:MRNS) Sees Significant Drop in Short Interest  2019/11/16 20:45:48 Modern Readers
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) was the target of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 2,950,000 shares, a decrease of 11.1% from the September 30th total of 3,320,000 shares. Based on an average daily volume of 1,370,000 shares, the days-to-cover ratio is […]

calendar